Anixa Biosciences, Inc. (FRA:CY71)
4.100
+0.040 (0.99%)
At close: Dec 4, 2025
Anixa Biosciences Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
135.53M EUR
Revenue Chart
* This company reports financials in USD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 36.49B |
| Siemens Aktiengesellschaft | 78.91B |
| Allianz SE | 105.02B |
| Deutsche Telekom AG | 121.02B |
| Siemens Energy AG | 39.08B |
| Rheinmetall AG | 11.00B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Deutsche Bank Aktiengesellschaft | 29.86B |
Anixa Biosciences News
- 18 days ago - Anixa Biosciences, Inc. (ANIX) Discusses Differentiated CAR-T Therapy and Breast Cancer Vaccine Clinical Programs Transcript - Seeking Alpha
- 18 days ago - Anixa Biosciences (ANIX) Unveils New Name for Ovarian Cancer Therapy - GuruFocus
- 19 days ago - Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization - PRNewsWire
- 23 days ago - Anixa Biosciences: Hard To Justify The Market's Optimism With An Upcoming Phase 1 Readout - Seeking Alpha
- 23 days ago - Water Tower Research Issues Statement Regarding Technical Interruption During Anixa Biosciences Fireside Chat - GlobeNewsWire
- 23 days ago - Anixa Biosciences (ANIX) Secures U.S. Patent for Breast Cancer Vaccine - GuruFocus
- 23 days ago - Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s - PRNewsWire
- 25 days ago - Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025 - PRNewsWire